产品描述
| 溶解性 |
|
| 存贮条件 | 储存温度-20°C |
| 产品介绍 | MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM. |
| 备注 | MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM |
| 生化机理 | MLN9708 immediately hydrolyzed to MLN2238, which is an N-capped dipeptidyl leucine boronic acid and preferentially bound to and inhibited the 20S proteasome with an IC50 value of 3.4 nM (Ki = 0.93 nM). |
| 别名 | 4-羧基-2-[(1R)-1-[[2-[(2,5-二氯苯甲酰基)氨基]乙酰基]氨基]-3-甲基丁基]-6-氧代-1,3,2-二氧硼杂环己-4-乙酸; MLN 9708; MLN-9708;Ixazomib; MLN 9708; MLN-9708;4-Carboxy-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-6-oxo-1,3,2-dioxaborinane-4-acetic acid |
